CIIE strives to promote innovation and cooperation, Boehringer Ingelheim and Shanghai Zhijiang Biotech signed a CDMO cooperation agreement for the new crown bispecific antibody drug

Boehringer Ingelheim will provide process optimization and commissioned production services for Shanghai Zhijiang Biotech's new coronary pneumonia antibody drug SYZJ001 Biopharmaceutical contract development and production services (CDMO) with international quality standards for innovative drugs empower domestic biotech companies to achieve "local innovation + global application" Boehringer Ingelheim's "Icebreaking Star" biopharmaceutical CDMO business debuts at the 4th CIIE Biomedical Zone

November 8, 2021 Shanghai/PRNewswire/ - At the just-opened 4th China International Import Expo, Boehringer Ingelheim, the world’s leading R&D-driven biopharmaceutical company, announced its partnership with Shanghai Zhijiang Biotechnology Co.

Dr.

In response to the development and variation trend of the global new crown pneumonia epidemic, Shanghai Zhijiang Biological and its shareholding company Shanghai Sanyou Biological jointly established a team in early 2020 to jointly develop the anti-negative crown bispecific antibody SYZJ001, which is an original anti-coronavirus treatment developed in China Drugs are also bispecific antibody drugs with leading global R&D progress

SYZJ001 is composed of a fully human IgG antibody molecule targeting the receptor binding domain (RBD) of the Spike protein of the SARS-CoV-2 virus and a humanized nanobody molecule.

At present, SYZJ001 has completed all pre-clinical research, and related achievements have applied for 3 patents, including 2 public patents, including 1 authorized patent (CN112250763B)

As the world's leading biopharmaceutical contract development and production service provider (CDMO), Boehringer Ingelheim will provide SYZJ001 with world-class quality production process development and optimization, raw solution and preparation cGMP production through its advanced technology platform and outstanding industry experience , And CMC declaration file support and other services

At present, China's biopharmaceutical industry has entered the fast lane of development, and the market demand for contract production business continues to increase

Lv Lilang, general manager of Shanghai Zhijiang Biotechnology Co.

As a national key development industry, biomedicine has always been a hot focus area of ​​the CIIE

About Boehringer Ingelheim

Boehringer Ingelheim is a leading global pharmaceutical company driven by research and development

Boehringer Ingelheim Biopharmaceuticals is the world's leading biopharmaceutical contract manufacturer

As a global leader in contract production of biopharmaceuticals, Boehringer Ingelheim Biopharmaceuticals is the first company to successfully provide commercialized biopharmaceutical production services in China

Shanghai Zhijiang Biotechnology Co.